- Home
- DEI vs PTGX Comparison
DEI vs PTGX Comparison
Compare DEI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEI
- PTGX
- Stock Information
- Founded
- DEI 1971
- PTGX 2006
- Country
- DEI United States
- PTGX United States
- Employees
- DEI N/A
- PTGX N/A
- Industry
- DEI Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- DEI Real Estate
- PTGX Health Care
- Exchange
- DEI Nasdaq
- PTGX Nasdaq
- Market Cap
- DEI 2.8B
- PTGX 2.4B
- IPO Year
- DEI 2006
- PTGX 2016
- Fundamental
- Price
- DEI $16.29
- PTGX $48.20
- Analyst Decision
- DEI Buy
- PTGX Strong Buy
- Analyst Count
- DEI 9
- PTGX 8
- Target Price
- DEI $18.50
- PTGX $66.50
- AVG Volume (30 Days)
- DEI 2.6M
- PTGX 1.5M
- Earning Date
- DEI 05-06-2025
- PTGX 05-06-2025
- Dividend Yield
- DEI 4.69%
- PTGX N/A
- EPS Growth
- DEI N/A
- PTGX N/A
- EPS
- DEI 0.13
- PTGX 4.23
- Revenue
- DEI $989,071,000.00
- PTGX $434,433,000.00
- Revenue This Year
- DEI $0.22
- PTGX N/A
- Revenue Next Year
- DEI N/A
- PTGX $8.12
- P/E Ratio
- DEI $122.63
- PTGX $11.40
- Revenue Growth
- DEI 0.46
- PTGX 624.05
- 52 Week Low
- DEI $12.50
- PTGX $24.22
- 52 Week High
- DEI $20.50
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- DEI 48.09
- PTGX 51.16
- Support Level
- DEI $15.74
- PTGX $51.06
- Resistance Level
- DEI $16.71
- PTGX $53.70
- Average True Range (ATR)
- DEI 0.47
- PTGX 2.05
- MACD
- DEI 0.05
- PTGX -1.08
- Stochastic Oscillator
- DEI 68.66
- PTGX 20.16
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is a real estate investment trust that acquires, develops, and manages office and multifamily properties in Los Angeles, California and Honolulu, Hawaii in the U.S. The company focuses on owning assets in communities with large supply constraints, such as the affluent neighborhoods of Los Angeles. The vast majority of Douglas Emmett's real estate portfolio is comprised of office buildings in Los Angeles. Most of these assets are located in the areas of Sherman Oaks, Woodland Hills, and Beverly Hills in terms of total square feet. Douglas Emmett derives nearly all of its income in the form of rental revenue from tenants. The vast majority of this also comes from its Los Angeles office buildings. The company's major tenants are legal, financial, and entertainment firms.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.